title: Protecting retinal ganglion cells.
abstract: Retinal ganglion cell degeneration underlies several conditions which give rise to significant visual compromise, including glaucoma, hereditary optic neuropathies, ischaemic optic neuropathies, and demyelinating disease. In this review, we discuss the emerging strategies for neuroprotection specifically in the context of glaucoma, including pharmacological neuroprotection, mesenchymal stem cells, and gene therapy approaches. We highlight potential pitfalls that need to be considered when developing these strategies and outline future directions, including the prospects for clinical trials.
authors.affiliation: Department of Clinical Neurosciences, John van Geest Centre for Brain Repair, University of Cambridge, Cambridge, UK.|Eye Department, Addenbrooke's Hospital, Cambridge, UK.
authors.forename: T Z
authors.initials: TZ
authors.lastname: Khatib
authors.affiliation: Department of Clinical Neurosciences, John van Geest Centre for Brain Repair, University of Cambridge, Cambridge, UK.|Eye Department, Addenbrooke's Hospital, Cambridge, UK.|Cambridge NIHR Biomedical Research Centre, Cambridge, UK.|Wellcome Trust-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK.
authors.forename: K R
authors.initials: KR
authors.lastname: Martin
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic; D015316:Genetic Therapy / Q000379:methods*; D005901:Glaucoma / Q000628:therapy; D006801:Humans; D045164:Mesenchymal Stem Cell Transplantation / Q000379:methods*; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D009901:Optic Nerve Diseases / Q000473:pathology / Q000628:therapy*; D012165:Retinal Ganglion Cells / Q000473:pathology*
chemical_list: D018696:Neuroprotective Agents